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Aicardi-Goutie`res syndrome (AGS) is a genetic encephalopathy whose clinical features mimic those of acquired in utero
viral infection. AGS exhibits locus heterogeneity, with mutations identified in genes encoding the 3′r5′ exonuclease
TREX1 and the three subunits of the RNASEH2 endonuclease complex. To define the molecular spectrum of AGS, we
performed mutation screening in patients, from 127 pedigrees, with a clinical diagnosis of the disease. Biallelic mutations
in TREX1, RNASEH2A, RNASEH2B, and RNASEH2C were observed in 31, 3, 47, and 18 families, respectively. In five
families, we identified an RNASEH2A or RNASEH2B mutation on one allele only. In one child, the disease occurred because
of a de novo heterozygous TREX1 mutation. In 22 families, no mutations were found. Null mutations were common in
TREX1, although a specific missense mutation was observed frequently in patients from northern Europe. Almost all
mutations in RNASEH2A, RNASEH2B, and RNASEH2C were missense. We identified an RNASEH2C founder mutation in
13 Pakistani families. We also collected clinical data from 123 mutation-positive patients. Two clinical presentations
could be delineated: an early-onset neonatal form, highly reminiscent of congenital infection seen particularly with
TREX1 mutations, and a later-onset presentation, sometimes occurring after several months of normal development and
occasionally associated with remarkably preserved neurological function, most frequently due to RNASEH2B mutations.
Mortality was correlated with genotype; 34.3% of patients with TREX1, RNASEH2A, and RNASEH2C mutations versus
8.0% RNASEH2B mutation–positive patients were known to have died ( ). Our analysis defines the phenotypicPp .001
spectrum of AGS and suggests a coherent mutation-screening strategy in this heterogeneous disorder. Additionally, our
data indicate that at least one further AGS-causing gene remains to be identified.
Author affiliations are listed in the Acknowledgments.
Received May 11, 2007; accepted for publication June 14, 2007; electronically published September 4, 2007.
Address for correspondence and reprints: Dr. Yanick J. Crow, Leeds Institute of Molecular Medicine, St James’s University Hospital, Level 9, Wellcome
Trust Brenner Building, Leeds LS9 7TF, United Kingdom. E-mail: Yanickcrow@mac.com
Am. J. Hum. Genet. 2007;81:713–725.  2007 by The American Society of Human Genetics. All rights reserved. 0002-9297/2007/8104-0015$15.00
DOI: 10.1086/521373
In 1984, Jean Aicardi and Franc¸oise Goutie`res, two emi-
nent French pediatric neurologists, reported eight chil-
dren from five families with an early-onset encephalop-
athy characterized by basal-ganglia calcification, white-
matter abnormalities, and a chronic cerebrospinal fluid
(CSF) lymphocytosis (MIM 225750).1 The presence of sib-
ling recurrences, affected females, and parental consan-
guinity suggested that the condition was inherited as
an autosomal recessive trait. However, the authors high-
lighted the risk of misdiagnosis of this disorder as the
sequelae of congenital infection, an observation that sub-
sequently led to the finding of raised levels of the antiviral
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Figure 1. Numbers and percentages of AGS-affected families with
biallelic mutations in TREX1, RNASEH2A, RNASEH2B, and RNA-
SEH2C; single RNASEH2A, RNASEH2B, and TREX1 mutations; and
those with no identifiable mutation(s).
Table 1. Summary Data of
Families with No Mutations in
TREX1, RNASEH2A, RNASEH2B,
or RNASEH2C
Sample n
Families 22
Patients 29
Consanguineous pedigrees 7
Patients with raised CSF WCC 26
Patients with raised CSF IFN-a 17
cytokine interferon alpha (IFN-a) in the CSF of affected
children.2
Phenotypic variability was recognized in the original
description of AGS and has since been confirmed by
others.3,4 Patients with apparently static or slowly progres-
sive disease, sometimes presenting after several months
of normal development, have been reported,1,5 whereas
other children have been reported with a neonatal onset
of features and early death.6 Notably, a number of early-
presenting cases have exhibited hepatosplenomegaly,
thrombocytopenia, and congenital microcephaly, further
emphasizing the clinical overlap with acquired in utero
infection.3
AGS is a genetically heterogeneous disorder. Elsewhere,
we localized the position of a gene (AGS1) causing AGS
on chromosome 3p217 and demonstrated that Cree en-
cephalitis, a severe infantile neurodegenerative disorder
found among the Canadian Cree Indian tribe of northern
Quebec, is allelic to AGS.8 Subsequently, we defined, again
by linkage analysis in consanguineous families, a second
disease locus (AGS2) on chromosome 13q14-21.9 Recent-
ly, we described mutations in genes encoding the 3′r5′
exonuclease TREX1 (or, DNase III [MIM 606609; Gen-
Bank transcript AAK07616 and nucleotide sequence NM_
033627], which causes AGS1)10 and the three nonallelic
subunits of the RNASEH2 protein complex (RNASEH2A
[MIM 606034; GenBank transcript AAH11748.1 and nu-
cleotide sequence NM_006397.2], RNASEH2B [MIM
610326; GenBank transcript AAH36744.1 and nucleotide
sequence NM_024570.1], and RNASEH2C [MIM 610330;
GenBank accession number AAH23588.1 and nucleotide
sequence NM_032193.3], which cause AGS4, AGS2, and
AGS3, respectively)11 in patients with AGS. The genetic
heterogeneity of the disease thus extends to include at
least four loci, with strong evidence of a common under-
lying pathogenic mechanism.
Here, we present clinical and molecular data from a large
cohort of AGS cases that define the phenotypic spectrum
of AGS and suggest a coherent mutation-screening strat-
egy for this heterogeneous disorder. Our data also indicate
that at least one further AGS-causing gene, accounting for
the disease in 17% of AGS-affected families in our study,
remains to be identified.
Material and Methods
Subjects
Subjects with a clinical diagnosis of AGS from 127 independent
pedigrees were recruited internationally through collaborating
physicians and the International Aicardi-Goutie`res Syndrome As-
sociation. Twenty-five families were seen by one of us (Y.J.C.). For
the remainder, information was provided by the clinician re-
sponsible for the care of the patient. Clinical, neuroimaging, and
laboratory data were obtained from medical records, magnetic
resonance imaging (MRI), and CT scans. Information about every
clinical characteristic was not available for all patients. All mu-
tation-negative families and those families in which only one
mutation could be identified included at least one child fulfilling
the following diagnostic criteria: neurological features of an en-
cephalopathy, intracranial calcification, negative investigations
for common prenatal infections, a CSF white-cell count (WCC)
5 white cells/mm3, and/or raised levels of IFN-a (12 IU/liter or
110 pg/ml) in the CSF. With consent, blood samples were ob-
tained from affected children, their parents, and unaffected sib-
lings. The study was approved by a U.K. Multicentre Research
Ethics Committee (reference number 04:MRE00/19).
Mutation Analysis
Genomic DNA was extracted from peripheral-blood leukocytes
by standard methods. PCR amplification of all coding exons and
conserved splice sites of TREX1 (AGS1), RNASEH2A (AGS4), RNA-
SEH2B (AGS2), and RNASEH2C (AGS3) was performed (primer se-
quences available on request). Purified PCR-amplification prod-
ucts were sequenced using dye-terminator chemistry and were
electrophoresed on ABI 3700 (Applied Biosystems), ABI 3100, or
MegaBace500 (Amersham Pharmacia) capillary sequencers. Ad-
ditionally, high-resolution melting curve analysis (MCA) was em-
ployed to screen RNASEH2A and RNASEH2B, with use of a Light-
Scanner (Idaho Technology) operating LightScanner v1.0.364
software. PCR incorporated the fluorescent dye LCGreen, and,
after completion, microtiter plates were transferred to the Light-
Scanner, with fluorescence data collection over the temperature
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Figure 2. Schematic representation of the TREX1 protein, with the corresponding position of the mutations identified in TREX1. Regions
1, 3, and 4 represent the exonuclease regions (Exo1-3), which coordinate the binding of 2 Mg2 ions required for catalysis. Region 2
represents the polyproline II motif. Region 5 represents the dileucine-repeat region. Numbers in parentheses after mutations represent
the number of mutated alleles identified. An asterisk (*) denotes the de novo mutation identified in one family.
Figure 3. Schematic representation of the RNASEH2B gene, with the position of identified mutations. Shaded areas with large numbers
indicate the specified exons. Numbers in parentheses after mutations represent the number of mutated alleles identified. Splice-site
variants and stop mutations always occur with a missense mutation.
range 70C–95C, as samples were melted. Samples were run both
“neat” and “spiked” with wild-type PCR product, to ensure de-
tection of homozygous variants. Data were analyzed using the
“manual scanning” setting. For DNA fragments with more than
one melting domain, as well as examination of the entire melting
curve, each separate melting domain was analyzed individually.
Samples in which the melting curve deviated from the wild-type
control were subjected to DNA sequencing. Mutations were clas-
sified as “null” if they were predicted to result in premature pro-
tein termination (including frameshifts, nonsense mutations, and
mutations altering splice-donor and -acceptor sequences); mis-
sense mutations were defined as “those causing the substitution
of one amino acid for another.” One hundred European control
alleles were sequenced for all four genes, and, in the case of RNA-
SEH2C, 100 South Asian alleles were also analyzed.
Statistical Analysis
x2 analyses, Kruskal-Wallis tests, and Mann-Whitney U tests for
nonparametric variables were performed using the Statistical
Package for the Social Sciences for Windows, version 12.01 (SPSS).
Results
Genetic Findings
Biallelic mutations in TREX1, RNASEH2A, RNASEH2B, and
RNASEH2C were observed in 31, 3, 47, and 18 families,
respectively. In three families, we could identify only a
single RNASEH2B mutation. In one family, we identified
a single mutation in RNASEH2A, and, in one further pa-
tient, we saw two putative RNASEH2A mutations on the
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Figure 4. Schematic representation of the RNASEH2C gene, with the position of identified mutations. Shaded areas with large numbers
indicate the specified exons. Numbers in parentheses after mutations represent the number of mutated alleles identified.
Figure 5. Schematic representation of the RNASEH2A gene, with the position of identified mutations and polymorphisms. Shaded
areas with large numbers indicate the specified exons. Numbers in parentheses after mutations represent the number of mutated alleles
identified. An asterisk (*) denotes polymorphisms included in the SNP database; a double asterisk (**) denotes synonymous changes
not found in controls or annotated as a SNP; ¶ denotes polymorphisms found in controls; † denotes polymorphisms found in combination
with RNASEH2B mutations; ‡ denotes putative mutation found in patients with only a single identified RNASEH2A change; a number
sign (#) denotes mutations found on one allele in a single patient.
same allele. In one patient, a single de novo heterozygous
TREX1 mutation was observed. Additionally, in 22 fami-
lies, no mutations were found (fig. 1 and table 1). None
of the identified mutations was annotated as a SNP in the
available databases, and none was present in alleles from
control subjects. Where tested, mutations segregated with
the disease in all families, and, except in the case of the
de novo heterozygous TREX1 mutation, all available par-
ents were heterozygous for a single mutation.
TREX1 is a single-exon gene encoding a 314-aa protein.
Mutations were seen throughout the gene (fig. 2). Eleven
mutations were null alleles. Eighteen families, 14 of which
were of northern European origin, were homozygous (15)
or compound heterozygous (3) for a c.341GrA transition
(R114H). Notably, all R114H homozygotes were also ho-
mozygous for the T allele of a SNP at c.531. This allele
exhibits highly significant (x2 test ) over-represen-P ! .001
tation in patients compared with controls (with a T allele
population frequency of 0.4), suggesting that the R114H
change might be an ancient founder mutation.
A total of 20 distinct mutations were identified in
RNASEH2B (a 308-aa protein) (fig. 3). All were missense
changes, except for five splice acceptor/donor mutations
and two stop mutations; the 12 affected individuals car-
rying these were all compound heterozygotes; the second
mutation was a missense change. All 50 families with a
change identified in RNASEH2B harbored at least one mu-
tation in exon 2, 6, or 7. The recurrent c.529GrA (A177T)
mutation was seen in a panethnic cohort of patients, in-
dicating that this is a mutation hotspot. In three families,
we could identify only a single RNASEH2B mutation. In
one of these families, the mutation had been maternally
inherited, whereas, in the other two families, parental sam-
ples were unavailable. The two heterozygous mutations
observed in these three pedigrees, c.529GrA and c.488CrT,
were seen recurrently in other cases.
We identified six distinct RNASEH2C (164-aa) missense
mutations in 18 families (fig. 4). Thirteen of these families
were of Pakistani origin, all of whom were homozygous
for the R69W (c.205CrT) mutation on a common hap-
lotype (data not shown), suggesting an ancient founder
effect. The remaining mutations were seen in a panethnic
cohort of patients.
Four children from three families were found to have
biallelic mutations in RNASEH2A (299 aa) (fig. 5). Four of
five mutations, one of which occurred in homozygous
form, were missense. In one family, we identified a single
mutation, c.704GrA (R236Q), in RNASEH2A that had been
inherited. In another patient, we identified two puta-
tive RNASEH2A mutations, c.717dup GC and c.719CrT
Table 2. Features of AGS-Affected Patients with Mutations in TREX1, RNASEH2A, and RNASEH2C Who Presented at Birth
Gene and
Gestation,
in wk
Measurement
at Birth
(percentile)
Neonatal Liver
Involvement Plateletsa
Neonatal
Seizures CSF WCC/mm3 (age)
CSF IFN-a IU/liter
(age) Status (age)Weight OFC
TREX1:
38 9th–25th 9th–25th HSM Low (39) Yes 52 (2 wk) NA Alive (11 years)
34 25th 50th HSM and ALFT Low (40) Yes 1 (25 mo); 2 (30 mo) 50 (25 mo) Deceased (6 years)
36 97th 97th No Low (50) No 27 (1 week); 17 (1 mo); 4 (8 mo) 25–50 (8 mo) Alive (7 years)
NR NR NR No NR No NR NR Alive (3 years)
NR NR NR No NR No 12 (4 mo) 200 (4 mo) Deceased (2 years)
37 9th 2nd No Low (38) Yes 17 (2 wk) 400 (2 mo) Alive (18 mo)
NR NR 25th HSM and ALFT Normal Yes NA NA Alive (3 years)
40 2nd–9th NR HSM and ALFT Normal No 0 (11 mo) 3 (11 mo) Deceased (6 years)
39 9th 9th Yes (unspecified) Normal No 18 (14 mo) 9 (14 mo) Alive (6 years)
40 .4th 2nd No Low (115) No 3 (2 d); 25 (7 d) 100 (2 wk); 200 (1 mo) Deceased (13 years)
38 2nd 2nd HSM Low (8)b Yes 12 (2 wk) 200 (2 wk) Alive (10 mo)
NR NR NR No Normal No 14 (4 mo); 25 (11 mo) 100 (4 mo) Alive (3 years)
40 .4th–2nd NR ALFT Low No 17 (5 mo); 6 (17 mo) NA Alive (9 years)
40 2nd–9th .4th HSM Low (53) No 57 (1 d); 124 (3 wk); 15 (1 mo); 10 (9 mo) 50 (9 mo) Alive (9 years)
40 !.4th !.4th HSM and ALFT Pancytopeniab No 0 (2 mo) 75 (2 mo) Alive (6 mo)
38 50th 50th No Normal No 108 (15 d); 20 (28 d); 6 (37 d) 36 (1 mo) Alive (1 years)
31 .4th .4th HSM Low No 0 (1 d); 2 (1 mo) 20 (1 mo) Alive (4 mo)
27 .4th–2nd 2nd–9th HSM and ALFT Low (15)c No NA NA Deceased (4.5 mo)
36 91st 50th No Low (37)c No 21 (2 wk) 200 (2 wk) Alive (2 mo)
RNASEH2C:
38 9th 9th–25th HSM and ALFT Low (47) Yes 25 (11 d); 70 (3 wk); 63 (2 mo) NA Deceased (2 years and 11 mo)
NR NR NR HSM Normal Yes NA NA Deceased (2 years and 8 mo)
40 25th 25th HSM Low (30) No NR 150 (3 mo) Alive (1 years)
RNASEH2A:
37 2nd !.4th HSM Pancytopeniab Yes 25 (1 d) NA Deceased (7 years)
NOTE.—OFC p occipitofrontal circumference; HSM p hepatosplenomegaly; ALFT p abnormal liver function tests; NA p not analyzed; NR p not recorded.
a Lowest value recorded #109/liter.
b Received transfusion of platelets and red cells.
c Received transfusion of platelets.
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Figure 6. Age (mo) at presentation by gene for patients with TREX1, RNASEH2A, RNASEH2B, and RNASEH2C mutations. With the Mann-
Whitney U test comparing age at presentation for patients with RNASEH2B mutations with that for patients with mutations in TREX1,
RNASEH2C, and RNASEH2A, . With the Kruskal-Wallis test comparing age at presentation with gene, .P ! .0005 P ! .0005
Figure 7. Age at death (in years) of patients with TREX1, RNASEH2A, RNASEH2B, and RNASEH2C mutations; x2 test comparing number
of deaths among children with TREX1, RNASEH2C, and RNASEH2A mutations against number of deaths among children with RNASEH2B
mutations ( ).Pp .001
(T241M), on the same allele. Parental samples were un-
available in this case. Finally, a number of polymorphisms
were also identified in the RNASEH2A gene.
Clinical Findings
Clinical data were collected for 123 individuals from 94
families with mutations in TREX1, RNASEH2A, RNASEH2B,
or RNASEH2C. The majority of children were born at term,
with a normal birth weight and head circumference, and
were discharged to home soon after delivery. However, 23
children (19 with TREX1 mutations, 3 with RNASEH2C
mutations, and 1 with a homozygous RNASEH2A muta-
tion) were affected at birth and required immediate sup-
port (table 2). These children presented with abnormal
neurology, acted jittery, and fed poorly. Eight experienced
neonatal seizures, and 15 demonstrated liver involvement,
with hepatosplenomegaly and/or raised transaminase lev-
els. Fifteen children had a thrombocytopenia, of whom
five required one or more platelet transfusions.
All other children presented at variable periods beyond
the first few days of life with, in the majority of cases, the
stereotypical subacute onset of a severe encephalopathy
characterized by irritability, inconsolable crying, inter-
mittent sterile pyrexias (40%), and a loss of skills. These
episodes usually lasted several months, beyond which
time the condition stabilized. Thereafter, no further dis-
ease progression was generally observed. Children with
RNASEH2B mutations presented significantly later than
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Figure 8. Examples of chilblain lesions seen in patients with AGS
Figure 9. Examples of intracranial calcification on CT scan of
patients with AGS. Calcification is seen in the basal ganglia (a
and b), dentate nuclei of the cerebellum (c), a periventricular
distribution (d), and within the deep white matter (e).
did those with mutations in TREX1, RNASEH2C, or RNA-
SEH2A (Mann-Whitney U test, ) (fig. 6); five chil-P ! .0005
dren had onset of symptoms at or beyond age 12 mo, after
a completely normal period of development.
The neurological phenotype of all patients was remark-
ably consistent, although variations were observed in the
severity of the associated neurological handicap. Typically,
patients were left with peripheral spasticity; dystonic pos-
turing, particularly of the upper limbs; truncal hypotonia;
and poor head control. Seizures were reported in 53% of
patients. A number of children were noted to demonstrate
a marked startle reaction to sudden noise, and, in several
cases, the differentiation from epilepsy was uncertain. Al-
most all patients were severely intellectually and physi-
cally impaired. However, six children with RNASEH2B mu-
tations had relatively preserved intellectual function, with
good comprehension and at least some retained speech.
One of these patients is of normal intelligence at age 19
years. A discrepancy in the severity of the neurological
outcome was observed between siblings in several fami-
lies. Most patients exhibited a severe acquired microceph-
aly, but, in those children with preserved intellect, the
head circumference was normal. Hearing was reported as
normal in almost every case. Visual function varied from
normal to cortical blindness. Ocular structures were al-
most invariably normal on examination.
Of all children with TREX1, RNASEH2A, and RNASEH2C
mutations, 34.3% were known to have died, the majority
(81%) by age 10 years (fig. 7). In contrast, only 4 (8%) of
50 patients with RNASEH2B mutations were deceased (x2
test, ), and 7 individuals with mutations in thisPp .001
gene are known to be aged 118 years (the oldest known
patient is aged 25 years).
Chilblain lesions were reported in 43% of patients and
were associated with mutations in all four genes. The le-
sions were usually situated on the feet but sometimes also
affected the hands and outer rim of the ears (fig. 8). Many
parents reported a direct relationship with cold temper-
atures, so the lesions were considerably worse during win-
ter months.
A number of rarer features were observed (table 3), in-
cluding raised levels of autoantibodies in six children,
treated hypothyroidism in an additional two cases, and
insulin-dependent diabetes mellitus (IDDM) in two other
patients.
Radiographic Findings
Neuroimaging demonstrated intracranial calcification var-
iably involving the basal ganglia, dentate nuclei of the
cerebellum, and deep white matter (fig. 9). Additionally,
there were associated abnormalities of the white matter,
with, in milder cases, high signal on T2-weighted MRI
situated at the anterior and posterior poles of the lateral
ventricles and, in more severely affected patients, a strik-
ing frontotemporal leukodystrophy with temporal cystic
lesions (fig. 10). In those subjects presenting in the peri-
natal period, calcifications and white-matter disease were
evident as early as the 1st d of life. Cortical atrophy was
a common feature in later scans, and a number of children
demonstrated significant brain-stem and cerebellar atro-
phy. Thinning and, in one subject, complete absence of
the corpus callosum were also observed.
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Figure 10. Spectrum of brain changes seen on MRI of patients
with AGS, showing hypointensity on T1-weighted imaging (a),
hyperintensity on T2-weighted imaging (b and c) of white matter,
extensive bitemporal cystic lesions (d), and significant thinning
of the brain stem and cerebellar atrophy (e).
Table 3. Infrequent Features Seen in AGS-Affected Patients
Phenotype
No. of Patients with Mutation
TREX1 RNASEH2B RNASEH2C RNASEH2A
Scoliosis 0 9 0 0
Cardiomegaly 4 0 1 1
Abnormal antibody profile 2 3 1 0
Preserved language 0 6 0 0
Demyelinating peripheral neuropathy 1 2 1 0
Congenital glaucoma 2 0 1 0
Micropenis 1 0 1 0
Hypothyroidism 1 1 0 0
IDDM 1 1 0 0
Transitory deficiency of antidiuretic hormone 1 0 0 0
Laboratory Findings
Where assayed, the number of white cells in the CSF was
normal (!5 cells/mm3) on 32 of 137 occasions (table 4).
The CSF WCC tended to fall with age, and the oldest age
at which a level 15 cells/mm3 was documented was 9 years
(Kruskal-Wallis test comparing CSF WCC with age group,
) (fig. 11). CSF IFN-a was recorded as elevated onP ! .0005
74 of 81 occasions tested. Again, levels of IFN-a tended
to fall with age (Kruskal-Wallis test comparing CSF IFN-a
with age group, ) (fig. 12). Of note, on 15 of 73P ! .0005
occasions where both were measured, the CSF WCC was
normal when the IFN-a level was raised. Conversely, three
children demonstrated a normal IFN-a titer with a raised
number of CSF white cells (table 5).
Pterin levels were recorded in 15 children (table 6). El-
evated levels of neopterin correlated well with raised num-
bers of CSF white cells and CSF IFN-a titers, although, on
two occasions, pterin analysis was normal in the presence
of a CSF lymphocytosis, whereas, in two cases, there was
marked elevation of CSF pterins with no associated in-
crease in CSF white-cell numbers.
Discussion
AGS is one of a number of disorders whose clinical features
mimic the sequelae of in utero viral infection.1,12–16 These
conditions are important to recognize because of the as-
sociated high risk of recurrence. Our experience indicates
that the possibility of a genetic disorder in subjects with
AGS is sometimes unrecognized until the birth of a second
affected child. In this regard, we note that no mention
was made of such genetic disorders in a recent review of
congenital infection.17 We suggest that an absence of de-
finitive evidence of an infectious agent in these circum-
stances should always raise the suspicion of AGS.
A subgroup of AGS-affected patients, typically those
with TREX1 mutations, presented at birth with abnormal
neurology, hepatosplenomegaly, elevated liver enzymes,
and thrombocytopenia, a picture highly reminiscent of
congenital infection. All other children presented at var-
iable times beyond the first few days of life, frequently
after a period of apparently normal development. The ma-
jority of these later-presenting cases exhibited a severe en-
cephalopathy with subacute onset that was characterized
by extreme irritability, intermittent sterile pyrexias, a loss
of skills, and a slowing of head growth. This encephalo-
pathic phase usually lasted several months. Interestingly,
the opinion of most pediatricians involved in the care
of these children was that there was no disease progres-
sion beyond the encephalopathic period. When death oc-
curred, the death was usually considered not to be due to
a regressive process but to be secondary to the neurological
damage incurred during the initial disease episode. RNA-
SEH2B mutations were associated with a significantly later
age at presentation, at or after age 12 mo in five cases,
and a lower mortality, with seven patients known to be
alive beyond age 18 years with no signs of disease pro-
gression. Also of note, six affected individuals with RNA-
SEH2B mutations demonstrated relatively preserved in-
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Figure 11. CSF white-cell counts by age in patients with TREX1, RNASEH2A, RNASEH2B, and RNASEH2C mutations. With Kruskal-Wallis
test comparing CSF WCC/mm3 with age group, .P ! .0005
Figure 12. CSF IFN-a titers by age in patients with TREX1, RNASEH2A, RNASEH2B, and RNASEH2C mutations. With Kruskal-Wallis test
comparing CSF IFN-a IU/liter with age group, .P ! .0005
tellectual function; one patient has a completely normal
intelligence quotient and head circumference at age 19
years, and his only feature is a spastic cerebral palsy with
associated intracranial calcification.
The observation of changes on brain imaging at birth
indicates an in utero onset of the disease process, in keep-
ing with the recording of prenatal raised levels of IFN-a.18
In contrast, our data also highlight the onset of AGS after
many months of normal development, raising the pos-
sibility that the condition might occur in considerably
older individuals too. The stimulus for the disease onset
is unknown, and why the disease tends to “burn out” after
several months is also not understood.
The cardinal features of AGS on brain imaging were in-
tracranial calcification, a leukodystrophy, and cerebral at-
rophy. The distribution and extent of the calcification was
variable and, in some cases, was observed in a periven-
tricular distribution highly suggestive of congenital infec-
tion. Affected sibling pairs have been described as discor-
dant for the presence of intracranial calcification, so this
feature should not be considered a prerequisite for the
diagnosis of AGS.1 Additionally, in several of our patients,
the intracranial calcification became evident only over a
period of months. Of importance, intracranial calcifica-
tion is not always recognized on MRI, the initial imaging
modality employed in most medical facilities. Conse-
quently, AGS should be considered in the differential di-
agnosis of an unexplained leukoencephalopathy, and CT
scanning is warranted in cases conforming to the clinical
scenarios we have outlined above. Of further note, some
patients demonstrated marked frontotemporal white-mat-
ter involvement with cyst formation, so that Alexander
disease (MIM 203450) and vanishing white-matter disease
(MIM 603896) were considered and tested for.
We identified 99 families with biallelic mutations in one
of the four genes known to cause AGS. Of these families,
78.8% had mutations in either TREX1 or RNASEH2B.
Moreover, all the patients with RNASEH2B mutations har-
bored at least one mutation in exon 2, 6, or 7. Thus, an
initial screen of TREX1 plus these three RNASEH2B exons,
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Table 5. Number of CSF
Examinations Showing
Discordance between Normal/
Abnormal Numbers of White
Cells and IFN-a Titer
WCC n
!5/mm3 with IFN-a 12 IU/liter 15
15/mm3 with IFN-a !2 IU/liter 3
Table 4. Number of Normal CSF White-
Cell and IFN-a Results of Examinations
of Mutation-Positive Patients with AGS
Age
(years)
No. (Total Recordings) of Patients
WCC !5/mm3 IFN-a !2 IU/Liter
0–1 9 (87) 0 (44)
1–3 12 (35) 3 (26)
4 11 (15) 4 (11)
together with an analysis for the recurrent c.205CrT
(R69W) RNASEH2C mutation in Pakistani patients, is
likely to identify 90% of all AGS-affected patients with
mutations in one of these four genes. In four families, we
were able to identify only a single RNASEH2A (one family)
or RNASEH2B (three families) mutation, and one further
child carried two putative RNASEH2A mutations on the
same allele; these cases are under further study. In addi-
tion, we studied 22 families in whom no AGS1–4 muta-
tions could be identified. Given the high detection rate
of biallelic mutations in AGS1–4, this finding strongly sug-
gests further genetic heterogeneity. Finally, only a single
patient was observed with a de novo heterozygous TREX1
mutation, indicating that such cases are unusual.19
The majority of TREX1 mutations are null alleles that
are predicted to produce truncated protein, which might
be inactive or disrupt protein complexes in the cell. Our
recent description of heterozygous TREX1 mutations as a
cause of dominant AGS suggests that some mutations may
have a dominant negative effect.19 Additionally, multiple
patients are homozygous or compound heterozygous for
a recurrent amino acid substitution, R114H, known to be
involved in stabilization of the TREX1 dimer20 and that
appears to abrogate TREX1 activity.10 In contrast to TREX1,
almost all mutations identified in RNASEH2A, RNASEH2B,
and RNASEH2C are missense changes, which suggests a
hypomorphic effect rather than a complete loss of RNA-
SEH2 enzyme function. Indeed, this mutational spec-
trum raises the possibility that biallelic null alleles in any
of these three genes might be lethal during embryonic
development.
Minimum diagnostic criteria for AGS are difficult to de-
fine. We have already highlighted above the absence of
intracranial calcification in some cases of AGS. A CSF lym-
phocytosis was originally described as a primary diagnos-
tic feature of the disease and was posited to differentiate
AGS from pseudo-TORCH syndrome.14 However, it is well
recognized that the level of white cells and IFN-a in the
CSF of AGS-affected patients falls to normal over the first
few years of life.21 Moreover, in our series, a normal CSF
WCC was documented in the presence of elevated CSF
IFN-a titers on 15 occasions. Blau et al.22 recently described
a possible variant of AGS associated with high levels of
CSF pterins. A number of mutation-positive AGS subjects
in our series demonstrated a similar pterin profile, which
should now be considered a marker of AGS. Whether the
cases described by Blau et al.22 have AGS or a separate
condition remains to be determined.
The chilblain lesions23 seen in 43% of AGS cases provide
a useful clinical marker of the disease and indicate an
immune pathology. The observation of a small number
of AGS-affected children with autoantibodies, hypothy-
roidism, and IDDM also suggests immune dysfunction.
We recently described heterozygous TREX1 mutations in
an autosomal dominant cutaneous form of systemic lupus
erythematosus (SLE [MIM 152700]) called “familial chil-
blain lupus” (MIM 610448).19 The precise functions of
TREX1 and the RNASEH2 complex are unknown. We pre-
dict that these nucleases are involved in removing nucleic
acid species produced during apoptosis and that a failure
of this process results in activation of the innate im-
mune system.24,25 This hypothesis would explain the phe-
notypic overlap of AGS with congenital infection and
some aspects of SLE,26–29 where an IFN-a–mediated innate
immune response is triggered by viral and host nucleic
acids, respectively.30,31
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